From Yahoo Finance: 2025-06-10 10:16:00

Caris Life Sciences plans to raise $423.5 million in an initial public offering, listing on Nasdaq under “CAI” with 23.5 million shares priced at $16 to $18 each. The company focuses on cancer, using AI and machine learning for disease analysis. In Q1 2025, Caris saw 50% revenue growth to $120.9 million.

Caris received FDA approval for MI Cancer Seek, a companion diagnostic test for targeted cancer treatments. Since 2008, the company has identified 915,000 unique pathogenic mutations, enabling customized therapies. Caris closed a $168 million private funding round in April, totaling $1.86 billion in capital raised since 2018.

Caris is part of a medtech IPO market resurgence, with Medline and Medtronic also considering public offerings. Medline and Medtronic plan potential IPOs as the medtech market shows signs of recovery.



Read more at Yahoo Finance: Caris Life Sciences plans $424M IPO